Loading…
FUTURE of Artificial Intelligence Act of 2020
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Fundamentally Understanding the Usability and Realistic Evolution of Artificial Intelligence Act of 2020 or the FUTURE of Artificial Intelligence Act of 2020 This bill directs the Chief Technology Officer, in the Office of Science and Technology Policy, to establish a Federal Advisory Committee on the Development and Implementation of Artificial Intelligence to advise the President on matters relating to the development of artificial intelligence, including: U.S. competitiveness, including the promotion of investment into the development of artificial intelligence; the U.S. workforce, including the potential for using artificial intelligence for rapid retraining of workers, due to the possible effect of technological displacement; education, including science, technology, engineering, and mathematics education to prepare workers as the needs of employers change; open sharing of data and research on artificial intelligence; international cooperation and competitiveness, including the competitive international landscape for artificial intelligence-related industries; matters relating to individual civil rights, including how rights are or will be affected by the use of artificial intelligence technology and whether such uses should be subject to additional controls, oversight, or limitations; and matters relating to urbanization and the development of smart cities.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2022 · fourth_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Animal Drug User Fee Act (P.L. 108-130); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023 Vaccine Injury Compensation Program.
Referred to the House Committee on Science, Space, and Technology.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $2,490,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $1,080,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Health Issues
Issues related to health care, including employee health care plans, HIPAA, health information technology, telehealth, including the Consolidated Appropriations Act, 2022 (Public Law 117-103), the Telehealth Modernization Act (H.R. 1332 / S. 368), the CONNECT Act (H.R. 2903 / S. 1512), the Telehealth Expansion Act (S. 1704), and the Ensuring Telehealth Expansion Act (H.R. 341), the Cures 2.0 Act (H.R. 6000), and the Food and Drug Amendments Act of 2023 (H.R. 7667), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Prescription Information Modernization Act of 2022 (H.R. 7559). Issues related to pharmacy, vaccines, and COVID-19 testing, including implementation of the CARES Act (Public Law 116-136).
Client expense: $4,980,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $2,610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office